- Home
- AMSF vs MRVI Comparison
AMSF vs MRVI Comparison
Compare AMSF & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- MRVI
- Stock Information
- Founded
- AMSF 1985
- MRVI 2020
- Country
- AMSF United States
- MRVI United States
- Employees
- AMSF N/A
- MRVI N/A
- Industry
- AMSF Accident &Health Insurance
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- AMSF Finance
- MRVI Health Care
- Exchange
- AMSF Nasdaq
- MRVI Nasdaq
- Market Cap
- AMSF 971.0M
- MRVI 809.2M
- IPO Year
- AMSF 2005
- MRVI 2020
- Fundamental
- Price
- AMSF $51.26
- MRVI $4.69
- Analyst Decision
- AMSF Buy
- MRVI Buy
- Analyst Count
- AMSF 2
- MRVI 10
- Target Price
- AMSF $59.50
- MRVI $10.28
- AVG Volume (30 Days)
- AMSF 98.9K
- MRVI 1.7M
- Earning Date
- AMSF 02-19-2025
- MRVI 02-25-2025
- Dividend Yield
- AMSF 2.91%
- MRVI N/A
- EPS Growth
- AMSF N/A
- MRVI N/A
- EPS
- AMSF 3.21
- MRVI N/A
- Revenue
- AMSF $315,182,000.00
- MRVI $276,920,000.00
- Revenue This Year
- AMSF N/A
- MRVI N/A
- Revenue Next Year
- AMSF $0.88
- MRVI $2.25
- P/E Ratio
- AMSF $15.84
- MRVI N/A
- Revenue Growth
- AMSF 2.81
- MRVI N/A
- 52 Week Low
- AMSF $41.97
- MRVI $4.28
- 52 Week High
- AMSF $60.24
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- AMSF 47.57
- MRVI 38.14
- Support Level
- AMSF $48.38
- MRVI $4.51
- Resistance Level
- AMSF $50.20
- MRVI $6.21
- Average True Range (ATR)
- AMSF 0.81
- MRVI 0.40
- MACD
- AMSF 0.16
- MRVI -0.09
- Stochastic Oscillator
- AMSF 84.38
- MRVI 11.47
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.